G1T48: Experimental Treatment for Estrogen Receptor-Positive, HER2-negative (ER+, HER2-) Breast Cancer

Scientific rationale and therapeutic potential

G1T48 is an oral selective estrogen receptor degrader (SERD) designed to inhibit estrogen receptor driven tumor growth as a single agent and in combination with other anti-cancer therapies, including CDK 4/6 inhibitors such as G1T38. G1T48 has the potential to be a best-in-class oral SERD.

Preclinical results (see: Publications)

G1 is recruiting patients for a Phase 1/2a trial in ER+, HER2- breast cancer

G1T48-01 Trial  
  • estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer (HER2-)
  • multi-center, open-label
  • G1T48 monotherapy
  • approximately 95 patients
  • ClinicalTrials.gov identifier: NCT03455270
  •  

    Click here for printable version of our G1T48 ER+ HER2- breast cancer clinical trial fact sheet